Category: Prohost Letters
Gilead Sciences - Still Way Undervalued
Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead Science’s ( GILD ) stock for years are upgrading it. Demonstrating time and time again its scientific genius in saving millions of people from...
Read More
December 29, 2022
0
Prohost Letter #444
Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predicting the pandemic, which continues to plague the...
Read More
March 8, 2021
0
Bear Market. Bad Market. Unpredictable Market.
Prohost Comprehensive Letter #450 BEAR MARKET. BAD MARKET. UNPREDICTABLE MARKET. Stock market investors usually learn from responsible sources about the status of the factors influencing the country’s economy. This is not what’s going on today. Investors have been unaware of...
Read More
May 17, 2022
0
A Flashback and Future Projections
Prohost Letter #445 A Flashback and Future Projections 1. A Follow-Up on Recently Posted News from ProhostBiotech 2. Answering Questions 3. Development-Stage Firms to Outperform 4. Oversold Revenue-Generating Firms 5. Tables with FAIR 2021 Targets for the Prohost Selected Firms...
Read More
March 24, 2021
0
Your Questions, Our Answers
Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues of Prohost Portfolio PLUS, as with all our Tables, we will include observations and target changes as well as any current news we feel...
Read More
March 28, 2021
0
Shorting Biotech Firms with Solid Fundamentals
Prohost Comprehensive Letter #451 Shorting Biotech Firms with Solid Fundamentals Unfair shorting of promising stocks seems to have become the norm during the harsh circumstances that not only the United States but several other countries have been living under for...
Read More
July 19, 2022
0
Re-Working Some Evaluated Biotechnology Firms
Prohost Portfolio PLUS #2 Re-Working Some Evaluated Biotechnology Firms Exelixis: 2020 and 2021 Wondering why Exelixis’ ( EXEL ) stock has looked paralyzed for more than two years? To know better about Exelixis the entrepreneur and Exelixis the creative scientific...
Read More
April 11, 2021
0
CureVac N.V.
Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about the German firm, CureVac N.V. ( CVAC ) , when the company announced business updates and financial results for its fourth quarter and full-year...
Read More
April 18, 2021
0
Celldex Therapeutics See Also: More of Your Questions Answered
Prohost Portfolio PLUS #4 Celldex Therapeutics Celldex Therapeutics ( CLDX ) stock is gaining momentum. On April 12, 2021 Celldex announced its presentation of promising data from its growing bispecific platform at the American Association of Cancer Research ( AACR ) Annual...
Read More
April 26, 2021
0
Treating Untreatable Disease - NASH
Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical trial data from the clinical-stage and revenue-generating biotech firms have demonstrated capability of...
Read More
October 13, 2022
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)